



Public Health
England

Protecting and improving the nation's health

A tool to test the long term health and cost impacts of air pollution at a local authority level

About Public Health England

Public Health England exists to protect and improve the nation's health and wellbeing, and reduce health inequalities. We do this through world-leading science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. We are an executive agency of the Department of Health and Social Care, and a distinct delivery organisation with operational autonomy. We provide government, local government, the NHS, Parliament, industry and the public with evidence-based professional, scientific and delivery expertise and support.

Public Health England
Wellington House
133-155 Waterloo Road
London SE1 8UG
Tel: 020 7654 8000

www.gov.uk/phe

Twitter: [@PHE_uk](https://twitter.com/PHE_uk)

Facebook: www.facebook.com/PublicHealthEngland

Prepared by: UK Health Forum



© Crown copyright 2018

You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit [OGL](https://www.ogilicence.gov.uk). Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

Published May 2018
PHE publications
gateway number: 2017858

PHE supports the UN
Sustainable Development Goals



Contents

About Public Health England.....	2
Contents.....	3
Background.....	4
Installing the tool.....	5
Running the simulation.....	6
3. Run length of the simulation.....	12
4. Select a cohort.....	13
5. Select a scenario.....	14
7. Dose Response.....	15
8. Running the cohort.....	16
9. Interpreting the outputs.....	17
10. Output Files.....	20
User guide appendices.....	22
Tool inputs – worked example.....	27
Economic results.....	33
References.....	50

Background

Air pollution has a significant impact upon public health, with both short (1-3) and long term health effects (4-6) increasing the risk of conditions such as asthma, cardiovascular, and respiratory disease, as well as risk of death. Knowing how air pollution is likely to impact upon health and related health costs over time is important for future policy and resource planning.

This user guide provides instructions on how to run the PHE Air Pollution Tool to answer this question.

Specifically, the tool has the ability to quantify the potential costs to the NHS and social care due to the health impacts of pollutants Nitrogen Dioxide (NO₂) and particulate matter (PM_{2.5}). The costs include primary care, secondary care, medication use, social care, and the combination of all the above costs.

The tool focusses on outdoor air pollution and has the ability to test different general '**what if**' scenarios for the reduction of air pollution, such as a given reduction in the levels of air pollution on the future impact on health and related cost.

Installing the tool

Step 1. Download and run the PHE_Air_Pollution_Setup.exe installer.

Step 2. Select where you want to install the tool and click Next. (If you set this to “Program Files”, you will need to run the tool with admin privileges every time you start it.)

Step 3. Select whether you want shortcuts placed on the Desktop and click Install.

After the tool is installed, you will find shortcuts for both running the tool and for opening the output folder in your Start menu in a “PHE_Air_Pollution_Tool” folder. If the relevant option was selected, shortcuts will also be placed on your desktop.

When you first run the tool, you will be prompted to accept the licence agreement. Please read over the terms and conditions then click Agree to continue.

Running the simulation

1. Initial Set Up: Location, Data Input and Risk Factor Selection

To set up a specific location, add population, exposure, cost data, and select the risk factor to be modelled, follow the instructions below:

STEP 1:

Select the geographical area of interest (Figure 1). This can be England or any local authority. If the geographical area you want to model is not in the drop down list of the 'geographical area' field, user should select 'Other region' as the geographical area.




Figure 1 Tool's Main Page

STEP 2:

Click on the **'View/Change Data Input'** button (Figure 1) to input your own population, exposure, and cost data. This will open a spreadsheet which consists of four tabs - 'Notes', 'POPULATION DATA', 'EXPOSURE DATA' and 'COSTS'.

The 'Notes' tab contains information on the type of data that can be input, definitions of the headers of the various data types as well as the source of the data contained in the remaining three tabs. **Please read the information on this tab before proceeding with any changes.**

The 'POPULATION DATA' tab (Figure 2) contains population data by single-years of age and sex for the selected geographical area by user - Please use the same structure when inputting in your own data (this applies to all the remaining tabs) (7).

Geographical area: Adur				
Males			Females	
Age	Count		Age	Count
0	370		0	357
1	411		1	339
2	427		2	368
3	396		3	436
4	410		4	378
5	424		5	376
6	393		6	356
7	392		7	369
8	350		8	318
9	344		9	345
10	351		10	305
11	328		11	294
12	358		12	281
13	314		13	305
14	297		14	274
15	365		15	340
16	386		16	338
17	390		17	323
18	361		18	310
19	358		19	281
20	278		20	255
21	325		21	253
22	272		22	269
23	293		23	305
24	322		24	330
25	334		25	285
26	278		26	330

Figure 2 The Data Format of the 'POPULATION DATA' tab

The 'EXPOSURE DATA' tab (Figure 3) holds information on the percentage of individuals of specific age-sex groupings in the population of the specified geographical area by user, who are at 'low', 'medium', or 'high' exposure to NO₂ or PM_{2.5}. Detailed information on 'low', 'medium', and 'high' exposure can be found under the 'Notes' tab¹. When inputting your own data, you should only add the proportions for the 'low' and 'medium' exposure groups and the proportion of individuals in the high exposure group will automatically be calculated to total 100%. Total exposure cannot be less than nor exceed 100%. Please note that due to calculations for which these exposure values are used, a minimum value of 0.00001 and a maximum of 99.99998 are set by default for each exposure level. The excel sheets will also make adjustments if the sum of exposures is greater than 100, which could result in the input data sheet displaying a negative percentage of people with high exposure. In the use of these values in future calculations this negative high exposure will be treated as 0.00001. Please take caution when setting exposure values. **See the exposure data format for males in Figure 3 (the same format applies to females).**

Note that all geographical areas have NO₂ and non background PM_{2.5} exposure² data.

¹ Data on air pollution exposure comes from high-resolution maps of NO₂ (200m x 200m resolution) and PM_{2.5} (100 x 100m resolution), originally developed for epidemiological studies in the UK and Europe. Air pollution estimates were assigned to each postcode in England. Exposure categories correspond to dividing the exposures across all postcodes in England into three equal parts (i.e. tertiles).

²The following assumptions were used to derive the exposure prevalences: i) In the case of an exposure prevalence being smaller than 0.00001, a minimum threshold of 0.00001 was chosen ii) The sum of the three exposures was set to 1. iii) The maximum of each prevalence was set to 1. If a prevalence was equal to 1, for regression reasons using logarithmic functions, a maximum exposure prevalence of 0.99998 was set.

Geographical area: Adur				
NO2				
Males				
Age Groups	Proportion in low NO2 exposure group (%)	Proportion in medium NO2 exposure group (%)	Proportion in high NO2 exposure group (%)	
0-4	38.213287	56.176712	5.610001	
5-9	37.962341	57.095676	4.941983	
10-14	40.707581	53.950195	5.342224	
15-19	40.707581	53.950195	5.342224	
20-24	37.886738	55.090332	7.02293	
25-29	37.945694	55.701172	6.353134	
30-34	36.579346	56.485142	6.935512	
35-39	38.877857	55.282753	5.83939	
40-44	40.651291	53.928471	5.420238	
45-49	40.808277	53.977966	5.213757	
50-54	42.032761	52.894329	5.07291	
55-59	43.385052	51.774918	4.84003	
60-64	41.360981	54.277508	4.361511	
65-69	42.301666	52.59655	5.101784	
70-74	44.015324	50.643097	5.341579	
75+	41.944473	53.572117	4.48341	
PM2.5				
Males				
Age Groups	Proportion in low PM2.5 exposure group (%)	Proportion in medium PM2.5 exposure group (%)	Proportion in high PM2.5 exposure group (%)	
0-4	0.199568	8.923941	90.876491	
5-9	0.2635	8.587987	91.148513	
10-14	0.48157	9.700171	89.818259	
15-19	0.481564	9.70017	89.818266	
20-24	0.435567	9.063688	90.500745	
25-29	0.311255	9.456488	90.232257	
30-34	0.253528	9.190531	90.555941	
35-39	0.242662	9.845113	89.912225	
40-44	0.270313	8.821769	90.907918	
45-49	0.285697	8.533694	91.180609	
50-54	0.326669	8.423581	91.24975	
55-59	0.337595	9.162415	90.49999	
60-64	0.276232	9.312863	90.410905	

Figure 3 The format of the males exposure data in the 'EXPOSURE DATA' tab

The 'COSTS' tab holds the annual costs per case for the types of costs being modelled (Primary Care Costs, Secondary Care Costs, Medication Costs, and Social Care Costs) for the NO₂ or PM_{2.5} associated diseases. See Figure 4 for the format of the costs table in the 'COSTS' tab.

Note that all geographical areas have cost data for England set as default.

NO2 Disease	Primary Care Costs (GBP/person/year)	Secondary Care Costs (GBP/person/year)	Medication Costs (GBP/person/year)	Social Care Costs (GBP/person/year)
asthma	21.280001	27.02	87.57	0.5
diabetes	375	536.75	276.880005	601.559998
lung cancer	51.73	466.630005	35.099998	89.379997
PM 2.5 Disease	Primary Care Costs (GBP/person/year)	Secondary Care Costs (GBP/person/year)	Medication Costs (GBP/person/year)	Social Care Costs (GBP/person/year)
coronary heart disease	71.57	1460.459961	818.599976	109.699997
copd	400.429993	587.47998	126.790001	85.300003
stroke	36.450001	722.840027	504.100006	76.050003
asthma	21.280001	27.02	87.57	0.5
diabetes	375	536.75	276.880005	601.559998
lung cancer	51.73	466.630005	35.099998	89.379997

Figure 4 The format of annual costs for the modelled diseases in the 'COSTS' tab

Within each tab users should only change/edit data in the yellow-highlighted cells (white and grey cells should not be edited). Numbers only should be entered (ie. and no letters).

You will need to save and close the excel sheet in order to return to the tool. This ensures that any edited data is not lost. Also note that you cannot return to the tool without closing the spreadsheet.

STEP 2:

Select the risk factor of interest by clicking on either the “**NO₂ Scenario Settings**” button for Nitrogen dioxide (NO₂) or the “**PM_{2.5} Scenario Settings**” button for particulate matter (PM_{2.5}). Clicking on either risk factor button will take you to the “Setup” page in Figure 5 where you can set the start and stop year of the simulation, the cohort, scenario and discounting rate as well as change the geographical location if required.

2. Setup

The “Setup” page is divided into 3 parts (Figure 5): 1st column is the key, 2nd contains the values / parameters which the user can adjust and 3rd is built-in comments to guide the user.³




Figure 5 Page Setup

You can select the geographical area, start and stop year of the simulation (until 2040), cohort type and gender, risk factor of interest, scenario to be simulated and discounting rate using the drop down menu under the “Value” field.

You can also display the population distribution by age in your selected geographical area by selecting ‘View/Graphs’ and age range of the cohort of interest. This will display the population distribution for your selection in the ‘Graphics’ tab. For example

³ Please note that that you can have the view of the tool in both dark and light mode. To switch between these modes: go to **View/Graph\Swap to dark mode** for dark mode and **View/Graph\Swap to light mode** for light mode.

A tool to test the long term health and cost impacts of air pollution at a local authority level

Figure 6 shows the procedure for viewing the “all ages” distribution for Adur. Click on “Setup” to return to the setup page after viewing the population distribution (Figure 7).




Figure 6 Steps to display Population Distribution by age




Figure 7 Distribution of the Population of Adur by age

3. Run length of the simulation

Select the **start** and **stop** year for the simulation from the “Setup” page (Figure 5). For example, you can run the simulation starting in 2015 and end it in 2025 (Figure 8). Note that 2040 is the last year that can be selected (Figure 9).

Key	Value
geographical area	Adur
start year	2015
stop year	2025

Figure 8 Selecting start and stop years of the simulation

Key	Value
geographical area	Adur
start year	2018
stop year	2040

Figure 9 Selecting 2018 as a star year and 2040 as the stop year

4. Select a cohort

Choose the cohort that you would like from the Setup page (Figure 5). See the “[18+][all exposure groups]” group below as an example (Figure 10)

cohort	[18+] [all exposure groups]
cohort gender	Male+Female

Figure 10 The [18+][all exposure groups] cohort

Cohorts and their meaning:

Cohort selection option	Definition
[1 to 18] [all exposure ⁴ groups]	all children in the country who are below the age of 18 years old, regardless of their risk to the pollutant under consideration
18+ [all exposure groups]	all adults in the country who are above the age of 18 years old, regardless of their risk to the pollutant under consideration
[18 to 39] [all exposure groups]	- all adults in the country who are 18-39 years old, regardless of their risk to the pollutant under consideration.
[40 to 64] [all exposure groups]	all adults in the country who are 40-64 years old, regardless of their risk to the pollutant under consideration.
65+ [all exposure groups]	all adults in the country who are 65 years or above, regardless of their risk of the pollutant under consideration.
[1 to 18] [Individuals exposed to high pollution levels]	all children in the country who are below the age of 18 years old and are 'at risk' of the pollutant under consideration ($\geq 20.5\mu\text{g}/\text{m}^3$ for NO_2 or $\geq 12.3\mu\text{g}/\text{m}^3$ for $\text{PM}_{2.5}$)
[18+] [Individuals exposed to high pollution levels]	all adults in the country who are above the age of 18 years old and are 'at risk' of the pollutant under consideration ($\geq 20.5\mu\text{g}/\text{m}^3$ for NO_2 or $\geq 12.3\mu\text{g}/\text{m}^3$ for $\text{PM}_{2.5}$)
[18 to 39] [Individuals exposed to high pollution levels]	all adults in the country who are 18-39 years old and are 'at risk' at risk of the pollutant under consideration ($\geq 20.5\mu\text{g}/\text{m}^3$ for NO_2 or $\geq 12.3\mu\text{g}/\text{m}^3$ for $\text{PM}_{2.5}$).
[40 to 64] [Individuals exposed to high pollution levels]	all adults in the country who are 40-64 years old and are 'at risk' of the pollutant under consideration ($\geq 20.5\mu\text{g}/\text{m}^3$ for NO_2 or $\geq 12.3\mu\text{g}/\text{m}^3$ for $\text{PM}_{2.5}$).
[65+] [Individuals exposed to high pollution levels]	all adults in the country who are 65 years old or above and are 'at risk' of the pollutant under consideration ($\geq 20.5\mu\text{g}/\text{m}^3$ for NO_2 or $\geq 12.3\mu\text{g}/\text{m}^3$ for $\text{PM}_{2.5}$).

5. Select a scenario

'% move to area with low $\text{NO}_2/\text{PM}_{2.5}$ ' is a hypothetical scenario in which a selected proportion (%) of the population who are in the 'medium' and 'high' exposure groups are shifted to a lower exposure group, i.e. an area where exposure to NO_2 is $< 20.5\mu\text{g}/\text{m}^3$ and $\text{PM}_{2.5}$ is $< 12.3\mu\text{g}/\text{m}^3$. For example when the user selects 20%, it will result in moving 20% of the entire medium and high exposure groups to the low exposure group. Figure 11 shows that you can move the entire modelled population to

⁴Note: dose-response relationships were available for adults, with the exception of asthma where dose-response functions were available also for children. Therefore, changes will only be observed with asthma in the child cohort.

an area with good air quality. The outputs here represent attributable cases due to air pollution.




Figure 11 The “100% move to area with good air quality” scenario

6. Discounting rates

You can also add discounting rate to the costs which will be output (Figure 12).




Figure 12. Adding discount rate

NICE recommend a discount rate of 1.5% for the UK (8), but this can be adjusted as necessary. The glossary defines discounting and describes the method used to calculate it.

7. Dose Response

The ‘% reduction applied to the dose-response’ field is only available for NO₂ since only evidence exists for the adjustment of NO₂ dose-response. This function is used to adjust the percentage of the original relative risk in the disease files to take the overlap of other pollutants into account. For example if the user selects 20% reduction from the drop down, this would mean they want to reduce the dose-response by 20%. A default of 60% has been set as this is the recommended value by COMEAP. Figure 13 shows an example of selecting 20% reduction of the original relative risk.




Figure 13 Selecting the percentage of the original relative risk in disease file to use in modelling disease

8. Running the cohort

Once you have completed the setup in the “Setup” tab, you can click the large **Run cohort** button at the bottom of the page (Figure 14). This will run the simulation. A progress bar will show you how the simulation is advancing. You can reset the simulation by closing the window and selecting the risk factor of interest again – all inputs will be defaulted back to the preloaded inputs.




Figure 14 Running the simulation for a cohort

9. Interpreting the outputs

9.1 Cost outputs

The cost outputs will be displayed in the “Output: Costs” tab ().

Baseline [B]: Estimated costs [ME/100,000], by year								
Year	2017	2018	2019	2020	2021	2022	2023	2024
[B] Primary Care Costs	2.706087	2.885176	3.043664	3.202553	3.355951	3.500782	3.637053	3.770371
[B] Secondary Care Costs	3.906883	4.148982	4.373718	4.600643	4.820744	5.027838	5.223366	5.414992
[B] Medication Costs	2.895652	3.034832	3.144569	3.261264	3.375470	3.483061	3.584826	3.676999
[B] Social Care Costs	3.921788	4.205646	4.463265	4.718431	4.964070	5.196093	5.414162	5.630964
[B] Combined Costs	13.430410	14.274634	15.025216	15.782890	16.516233	17.207771	17.859406	18.493326

Scenario [S]: Estimated costs [ME/100,000], by year								
Year	2017	2018	2019	2020	2021	2022	2023	2024
[S] Primary Care Costs	2.706087	2.879293	3.035974	3.191394	3.337096	3.478132	3.610634	3.740300
[S] Secondary Care Costs	3.906883	4.140521	4.362329	4.584295	4.792647	4.995056	5.185193	5.371597
[S] Medication Costs	2.895652	3.023271	3.138894	3.253027	3.361557	3.466341	3.565322	3.654799
[S] Social Care Costs	3.921788	4.199582	4.450921	4.700524	4.933805	5.159754	5.371776	5.582720
[S] Combined Costs	13.430410	14.242666	14.988117	15.729240	16.425104	17.099281	17.732925	18.349415

Differences (Baseline relative to Scenario) of Estimated costs [ME/100,000], by year								
Year	2017	2018	2019	2020	2021	2022	2023	2024
[B-S] Primary Care Costs	0.000000	0.005883	0.007691	0.011159	0.018855	0.022649	0.026419	0.03
[B-S] Cumulative Primary Care Costs	0.000000	0.005883	0.013573	0.024733	0.043588	0.066237	0.092656	0.12
[B-S] Secondary Care Costs	0.000000	0.008461	0.011389	0.016348	0.028097	0.032782	0.038173	0.04
[B-S] Cumulative Secondary Care Costs	0.000000	0.008461	0.019850	0.036198	0.064294	0.097077	0.135250	0.17
[B-S] Medication Costs	0.000000	0.011560	0.005675	0.008236	0.013913	0.016720	0.019504	0.02
[B-S] Cumulative Medication Costs	0.000000	0.011560	0.017235	0.025472	0.039385	0.056104	0.075608	0.09

Figure 15 Cost Outputs after simulation run

Using the primary care costs as an example, the displayed costs represent the total primary care costs for each scenario for all the modelled diseases in each year of the simulation. You can see the baseline costs for each year under the field “Baseline [B]”; and the cost for each year for the specified scenario under the field “Scenario [S]”. The difference in cost between the latter and the former scenarios for each year is presented under the “Difference [B-S]”.

Note that the explanation also applies to Secondary Care, Medication, Social care and Combined costs.

Cumulative cost difference [B-S]: Appearing under each cost in the differences section, you will see the cumulative cost difference. This is the moving sum of the difference in cost between the baseline and the scenario across the duration of the simulation run. This field is populated when some proportion of the population moves from areas of high exposure to low exposure.

You can also display the cost differences and cumulative cost differences by year by clicking on View/Graphs/Draw Cost Differences by year and View/Graphs/Draw Cumulative Cost Differences by year, respectively as illustrated in Figure 16 and Figure 17 or by right clicking a row of interest in the cost difference table (after drawing the cost figure of interest, you might need to refresh the difference table by clicking on the scroll bar).




Figure 16 How to display cost graphs




Figure 17 Combined cost differences by year

9.2 Output: Disease Prevalence

You will also notice the appearance of the “Output: Disease Prevalence” tab at the top of the page after the run.

The user should be able to see three tables in ‘Output: Disease prevalence (Figure 18).

1. **‘Baseline table’**: shows the number of people living with each modelled disease in a given year, and the number of people who have died in each year as a baseline, if nothing changes.
2. **‘Scenario table’**: shows the number of people living with each modelled disease in a given year, and the number of people who have died in each year in the scenario that was specified (NOTE: if the scenario you selected was ‘No Change’ then the Baseline table and Scenario table will show the same data).
3. **‘Changes table’**: Shows the difference between the **‘Baseline table’** and the **‘Scenario table’**. Note that you can also draw the difference by right clicking on the row of the disease of interest (after drawing the figure of interest, you might need to refresh the difference table by clicking on the scroll bar).

A tool to test the long term health and cost impacts of air pollution at a local authority level

The screenshot shows the AIR Adur software interface with the 'Output: Disease Prevalence' tab selected. It displays three tables: Baseline [B], Scenario [S], and Differences (Baseline relative to Scenario). The data is presented as a grid with columns for years from 2017 to 2027 and rows for different diseases and deaths.

Baseline [B]: prevalence by disease by year per 100,000 of the surviving cohort population and deaths by year per 100,000											
Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027
[B] asthma	12500	12787	12877	13064	13277	13489	13712	13824	14075	14203	14471
[B] diabetes	6480	7063	7613	8173	8731	9280	9818	10368	10885	11420	12000
[B] lung cancer	195	162	158	159	163	165	169	173	176	180	186
[B] deaths	0	1482	3018	4515	6213	7910	9697	11483	13507	15473	17647

Scenario [S]: prevalence by disease by year per 100,000 of the surviving cohort population and deaths by year per 100,000											
Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027
[S] asthma	12500	12685	12877	13064	13277	13489	13712	13824	14075	14203	14471
[S] diabetes	6480	7053	7592	8142	8678	9215	9741	10279	10795	11316	11882
[S] lung cancer	195	161	157	158	160	164	168	172	175	179	184
[S] deaths	0	1482	3018	4515	6213	7910	9697	11483	13507	15473	17647

Differences (Baseline relative to Scenario) by disease by year per 100,000 and deaths by year per 100,000											
Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027
[B-S]asthma	0	102	0	0	0	0	0	0	0	0	0
[B-S]diabetes	0	10	21	31	53	65	77	89	90	104	118
[B-S]lung cancer	0	1	1	1	3	1	1	1	1	1	2
[B-S]deaths	0	0	0	0	0	0	0	0	0	0	0

Figure 18 Output: Disease prevalence

10. Output Files

All the outputs are saved in the output folder under the country, risk factor, and time and date of the run. You can access the output folder by doing one of the following:

- File\Open Output Folder
- Opening the Output Folder shortcut from the start menu under All Programs > PHE_Air_Pollution_Tool
- Or from the shortcut on the Desktop if you enabled this during installation.

Output Files	Content of Output Files
Base_Prev.txt	The baseline prevalence rate per 100,000 by year
Sce_Prev.txt	The scenario prevalence rate per 100,000 by year
Diff_Prev.txt	The difference in prevalence cases between baseline and scenario
Sce_Costs.txt	The scenario cost rate (£M per 100,000) by year
Base_Costs.txt	The baseline cost rate (£M per 100,000) by year (all costs included)
Diff_Costs.txt	The difference in costs between baseline and scenario
{COST_PARAMETER}_Input_Data.txt	A list of the cost per case input data used by the simulation for this cost parameter (£/patient/year).
{COST_PARAMETER}_{Baseline/Scenario/Difference}	Per disease costs (£m per 100,000 people) for this cost type in the baseline/scenario/difference between baseline and scenario runs
Assorted TRJ files	Trajectories created for each sub-population There are 6 parameters: (age, sex, intervention year, risktype depending on the risk factor of interest (8: NO ₂ and 9: PM _{2.5}) p-tile is the percentile of the individual, weight and the exposure data).

Because of the nature of asthma as a disease, some fluctuations may be observed in the outputs. These are explained in more detail in appendix 4.

User guide appendices

Appendix 1 provides a glossary of terms.

Appendix 2 provides some worked examples from the tool to ease interpretation of the outputs. It may be a useful exercise to run the same parameters and follow the comparisons provided.

Appendix 3 provides an explanation of how the costs are calculated.

Appendix 1: Glossary of terms

1. Baseline – This refers to the ‘steady state’ of the risk factor assuming no change from current exposure levels.
2. Data pack - This is a single file which contains all of the disease and population statistics required by the tool.
3. Disease exposure – this refers to the number of days per person that an individual has a disease. For example, 500 diabetes days refers to the number of days an individual is alive and lives with a disease.
4. Distribution –the frequency of various outcomes in a sample population. The frequency or count of the occurrences of values within a particular group or interval, and in this way, the table summarizes the distribution of values in the sample.
5. Incidence – the occurrence of *new* cases of the disease – not to be confused with prevalence.
6. Prevalence – this is the total number of cases of a disease in a particular population. This indicates how widespread the disease is.
7. Probability – this is the chance of a disease occurring. Probability always lies within 0 and 1.
8. Simulation – the imitation of a real-world process or system over time, in this case the simulation of a virtual country population.
9. Discounting – A technique which allows the calculation of present values of inputs and benefits which accrue in the future. Discounting is based on a time preference which assumes that individuals prefer to forego a part of the benefits if they accrue it now, rather than fully in the uncertain future. By the same reasoning, individuals prefer to delay costs rather than incur them in the present. The strength of this preference is expressed by the discount rate which is inserted in economic evaluations.

The equation below shows how discounting works on the individual costs (primary care, secondary care, medication and social care costs) for each scenario for each simulated year:

$$= \left(\sum_{j=1}^{\text{no.of diseases}} \text{Prevalence}_{j,i} * \text{Cost}_j \right) * \left(1 - \frac{\text{Discount rate}}{100} \right)^i$$

Where:

“i” = each year of the simulation (for example if your simulation starts from 2017 and ends at 2020, i = 1 will refer to 2017, i = 2 will be 2018 and so on to 2020). In effect the value of “i” depends on the run duration of the simulation.

Prevalence_{ji} = Prevalence of disease_j per scenario in each year of the simulation
disease_j = the diseases being run in the simulation

A tool to test the long term health and cost impacts of air pollution at a local authority level

Cost_j = cost type per case of disease;

Discount rate = input discounting rate by user


Appendix 2. Example of analysis

In order to ease interpretation of the findings from the tool, we have provided some example analyses below.

Comparison of 2 local authorities: South Lakeland versus Lambeth

Demographic comparison

Figure 19 and Figure 20 show the population distributions for Lambeth and South Lakeland, produced from:



From these figures we can deduce that:

- The largest proportion of the population is aged between 30-39 years old in Lambeth and 50-69 years old in South Lakeland.
-
- Around 64% and 38% of the population are younger than 40 years old in Lambeth and South Lakeland respectively. Therefore, Lambeth has a much younger population than South Lakeland.




Figure 19 Demographics of Lambeth



Figure 20 Demographics of South Lakeland

Exposure Comparison

In terms of the 3 categories described for both pollutants (i.e. Low: NO₂ < 20.5 microgram m⁻³, medium: NO₂ from 20.5 to 28.5 microgram m⁻³, high: NO₂ >= 28.5 microgram m⁻³ and low: PM_{2.5} < 12.3 microgram m⁻³, medium: PM_{2.5} from 12.3 to 13.5 microgram m⁻³, high: PM_{2.5} >= 13.5 microgram m⁻³), 99% of the Lambeth population lives in the most highly polluted categories for both NO₂ and PM_{2.5}, whereas only between 4% and <1% of the South Lakeland population live in high exposure NO₂/PM_{2.5} areas. These figures can be seen in the excel sheet data input of the tool and can be summarised by the Table 1 and Table 2.

Table 1. Average prevalence for the three air pollution categories of PM_{2.5} in 2015 for adults for South Lakeland and Lambeth

Pollutant	Population	Low pollution prevalence (%)	Medium pollution Prevalence (%)	High air pollution Prevalence (%)
PM _{2.5}	Lambeth, adults, male	0.0	0.0	100.0
PM _{2.5}	Lambeth, adults, female	0.0	0.0	100.0
PM _{2.5}	South Lakeland, adults, male	100.0	0.0	0.0
PM _{2.5}	South Lakeland, adults, female	100.0	0.0	0.0

Table 2. Average prevalence for the three air pollution categories of NO₂ in 2015 for adults for South Lakeland and Lambeth

Pollutant	Population	Low pollution prevalence (%)	Medium pollution Prevalence (%)	High air pollution Prevalence (%)
NO ₂	Lambeth, adults, male	0.0	0.0	100.0
NO ₂	Lambeth, adults, female	0.0	0.0	100.0
NO ₂	South Lakeland, adults, male	83.6	12.0	4.4
NO ₂	South Lakeland, adults, female	83.8	11.9	4.3

Tool inputs – worked example

For a worked example of the tool, you could use the following input parameters:

Start year: 2017

Stop year: 2037

Cohort: [18+] [all exposure groups]

Cohort gender: Male + Female

Discounting: 1.5%

% reduction applied to RR: 60.0% (For NO₂)

Scenario: 100% move to area with low air pollution

Results

Some results can be extracted from the baseline epidemiological and economic results:

- For NO₂, South Lakeland (Table 9) with a large proportion of elderly people in its population has a larger prevalence rate of lung cancer and diabetes compared to Lambeth (Table 3) between 2017 and 2037 (The same pattern of results can be derived for the 4 types of costs) (Table 15, Table 21).
- Similarly, for PM_{2.5}, as expected South Lakeland (Table 12) with a large proportion of elderly in its population has a larger rate of CHD, COPD, diabetes and lung cancer compared to Lambeth (Table 6) between 2017 and 2037. The same analysis can be derived for the 4 types of costs (Table 18, Table 24).

A variety of results can be extracted to illustrate the effect of the interventions:

- As expected, the impact of the NO₂ and PM_{2.5} interventions on South Lakeland which has very low NO₂ and PM_{2.5} exposures, is negligible. Note that the instability of the prevalence gains and costs avoided is due to the uncertainty caused by the fact that most individuals in the cohort are not affected by the intervention.
-
- The impact of the NO₂ scenario (ie. 100% of the population move to an area with low air pollution) (Table 5) on Lambeth is the following:
 - 253 prevalence cases per 100,000 of population in asthma are expected to be avoided by 2037
 - 715 prevalence cases per 100,000 of population in diabetes are expected to be avoided by 2037
 - 6 prevalence cases per 100,000 of population in lung cancer are expected to be avoided by 2037

- The impact of the PM_{2.5} scenario (ie. 100% of the population move to area with low air pollution) on Lambeth is the following (Table 8. Difference (Baseline relative to Scenario) by disease per 100,000 and deaths by year per 100,000 in Lambeth (Table 8):
 - 662 prevalence cases per 100,000 of population in CHD are expected to be avoided by 2037
 - 935 prevalence cases per 100,000 of population in diabetes are expected to be avoided by 2037
 - 10 prevalence cases per 100,000 of population in lung cancer are expected to be avoided by 2037
 - Note that there is no published associated asthma effect on adults and consequently, the results are to be interpreted with caution for this specific cohort: the only cases avoided are caused by ageing of the children over the years. Therefore the trends appear bumpy and unstable.
- The costs avoided by moving 100% of the population to an area with low level of air pollution:
 - As expected, the impact of this scenario in South Lakeland, which has very low NO₂ and PM_{2.5} exposures, is negligible. Note that the instability in the costs avoided are due to the uncertainty caused by the fact that most individuals in the cohort are not affected by the intervention. (Table 23, Table 26)
- The impact of the NO₂ scenario (ie. 100% of the population move to area with low air pollution) (Table 17) on Lambeth is the following:
 - A cumulative cost of £2.42 million per 100,000 of population in primary care are expected to be avoided by 2037
 - A cumulative cost of £3.48 million per 100,000 of population in secondary care are expected to be avoided by 2037
 - A cumulative cost of £1.91 million per 100,000 of population in medication are expected to be avoided by 2037
 - A cumulative cost of £3.83 million per 100,000 of population in social care are expected to be avoided by 2037

Epidemiological results

Lambeth

NO2

Baseline

Table 3. Baseline prevalence by disease by year per 100,000 of the surviving cohort population and deaths by year per 100,000 in Lambeth

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037
[B] asthma	13	13	13	14	14	14	14	14	15	15	15	15	15	16	16	16	16	16	16	17	17
[B] diabetes	60	77	95	13	31	51	70	90	00	21	43	65	78	02	15	41	57	72	89	18	38
[B] lung cancer	0	5	3	2	9	1	7	4	7	7	7	7	4	0	9	0	3	3	5	6	6
[B] deaths	33	37	41	46	50	54	58	63	67	72	77	82	87	92	97	10	10	11	11	12	13
	80	91	86	06	22	44	83	37	79	39	19	04	03	09	17	25	80	41	87	57	06
	79	68	68	69	71	74	78	82	85	88	93	98	10	10	11	11	12	13	13	14	15
	0	54	11	16	22	29	35	42	49	56	64	72	81	89	99	10	11	12	14	15	16
		6	12	67	81	12	73	21	43	75	62	39	08	80	26	87	98	99	15	34	68
															7	2	4	5	0	6	

Scenario

Table 4. Scenario prevalence by disease by year per 100,000 of the surviving cohort population and deaths by year per 100,000 in Lambeth

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037
[S] asthma	13	13	13	14	14	14	14	14	15	15	15	15	15	15	16	16	16	16	16	16	17
[S] diabetes	60	77	95	13	31	50	60	79	00	11	32	54	67	80	04	18	33	61	78	95	13
[S] lung cancer	0	5	3	2	9	9	2	8	5	0	7	8	2	0	7	4	1	0	1	5	3
[S] deaths	33	37	41	44	48	52	56	60	64	69	73	78	82	87	91	96	10	10	11	11	12
	80	50	15	94	79	69	65	75	95	10	44	06	58	17	89	89	19	71	22	76	35
	79	67	66	67	69	72	75	79	82	85	90	95	10	10	10	11	12	12	13	13	14
	0	54	11	16	22	29	35	42	49	56	64	72	80	89	99	10	11	12	14	15	16
		6	12	67	81	02	63	10	32	64	40	27	85	68	14	85	85	99	15	34	55
															2	7	4	5	0	0	

Differences

Table 5. Difference (Baseline relative to Scenario) by disease per 100,000 and deaths by year per 100,000 in Lambeth

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037
[B-S]asthma	0	0	0	0	0	2	10	10	2	10	11	10	11	22	11	22	24	11	11	23	25
[B-S]diabetes	0	41	71	11	14	17	21	26	28	32	37	39	44	49	52	56	61	70	65	80	71
[B-S]lung cancer	0	1	2	2	2	2	3	3	3	3	3	3	3	4	3	4	3	3	4	5	6
[B-S]deaths	0	0	0	0	0	10	10	11	11	11	22	12	23	12	12	25	12	0	0	0	13
																5					6

PM2.5

Baseline

Table 6. Baseline prevalence by disease by year per 100,000 of the surviving cohort population and deaths by year per 100,000 in Lambeth

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037
[B] coronary heart disease	124	13	13	14	15	15	16	17	17	18	19	19	20	21	22	23	24	25	25	27	280
[B] copd	108	10	93	90	86	85	82	83	82	84	84	88	89	92	95	10	10	10	11	11	120
[B] stroke	138	13	13	13	13	14	14	14	14	14	14	14	15	15	15	16	16	17	18	18	195
[B] asthma	136	13	13	14	14	14	14	14	15	15	15	15	15	16	16	16	16	16	16	17	174
[B] diabetes	338	37	41	46	50	54	58	63	67	72	76	81	86	91	96	10	10	11	11	12	129
[B] lung cancer	79	69	68	69	71	74	77	81	84	88	92	97	10	10	11	11	12	13	13	14	151
[B] deaths	0	68	14	21	28	36	43	51	60	68	77	86	95	10	11	12	13	15	16	17	191
		9	30	14	81	05	95	41	00	15	24	01	89	57	60	74	89	07	41	64	90
														1	7	0	5	5	4	7	

Scenario

Table 7. Scenario prevalence by disease by year per 100,000 of the surviving cohort population and deaths by year per 100,000 in Lambeth

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037
[S] coronary heart disease	12	12	13	13	13	14	14	14	15	15	15	16	16	17	17	18	18	19	20	20	21
[S] copd	10	98	88	82	75	72	68	66	64	64	63	64	64	66	67	70	71	74	76	80	82
[S] stroke	13	13	13	13	13	13	13	13	13	13	13	14	14	14	14	15	15	16	16	17	17
[S] asthma	13	13	13	14	14	14	14	14	15	15	15	15	15	16	16	16	16	16	16	17	17
[S] diabetes	60	79	99	19	39	59	81	91	13	35	47	70	84	08	24	36	53	81	99	17	37
[S] lung cancer	79	66	63	64	66	68	71	75	78	81	85	90	94	98	10	10	11	12	12	13	14
[S] deaths	0	68	14	20	28	35	42	50	58	66	74	83	92	10	11	12	13	14	15	16	18
		9	20	93	38	41	97	20	31	21	81	07	54	16	23	10	25	41	60	82	20
														9	5	8	0	6	7	2	3

Differences

Table 8. Difference (Baseline relative to Scenario) by disease per 100,000 and deaths by year per 100,000 in Lambeth

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037
[B-S]coronary heart disease	0	40	71	10	13	16	20	23	26	30	32	36	38	42	45	49	53	56	59	63	66
[B-S]copd	0	29	56	81	10	12	14	16	17	19	21	23	24	26	27	30	31	33	34	36	38
[B-S]stroke	0	11	21	21	31	42	43	54	55	67	78	80	92	94	95	12	12	13	13	15	15
[B-S]asthma	0	0	1	3	6	9	-	17	24	-	35	-	48	-	-	92	94	-	3	3	26
[B-S]diabetes	0	40	81	12	15	20	23	28	31	35	39	44	47	52	56	61	66	69	71	77	93
[B-S]lung cancer	0	3	5	5	5	6	6	6	6	7	7	7	8	8	8	8	8	10	9	10	10
[B-S]deaths	0	0	10	21	43	64	98	12	16	19	24	29	33	40	37	63	64	65	80	82	98
								1	9	4	3	4	5	2	2	2	5	9	7	5	7

South Lakeland

NO2

Baseline

Table 9. Baseline prevalence by disease by year per 100,000 of the surviving cohort population and deaths by year per 100,000 in South Lakeland

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037
[B] asthma	12	12	12	12	13	13	13	13	13	14	14	14	14	14	15	15	15	15	15	16	16
[B] diabetes	30	50	70	91	14	27	51	65	80	08	26	44	64	83	07	14	40	65	79	04	23
[B] lung cancer	0	0	8	3	5	1	8	7	9	5	9	3	3	4	2	7	6	6	7	8	3
[B] deaths	71	78	84	90	96	10	10	11	11	12	13	13	14	14	15	15	16	16	17	17	18
	90	25	31	39	29	22	81	40	96	55	07	70	14	70	20	81	23	78	24	68	22
	22	18	17	18	18	19	19	20	20	21	21	22	22	23	23	24	24	24	24	25	25
	0	3	8	0	5	8	3	8	1	5	2	8	2	4	1	7	1	4	8	4	9
	0	16	33	49	68	87	10	12	15	17	19	22	25	27	31	34	37	41	44	48	53
		26	16	87	72	78	80	86	07	37	90	39	15	87	06	04	55	04	92	58	13
							3	7	5	1	4	9	6	7	2	8	2	4	8	8	9

Scenario

Table 10. Scenario prevalence by disease by year per 100,000 of the surviving cohort population and deaths by year per 100,000 in South Lakeland

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037
[S] asthma	12	12	12	12	13	13	13	13	13	14	14	14	14	14	15	15	15	15	15	16	16
[S] diabetes	30	50	70	91	14	27	51	65	80	08	26	44	64	83	07	14	40	65	79	04	23
[S] lung cancer	0	0	8	3	5	1	8	7	9	5	9	3	3	4	2	7	6	6	7	8	3
[S] deaths	71	78	84	90	96	10	10	11	11	12	13	13	14	14	15	15	16	16	17	17	18
	90	15	20	18	18	20	79	40	96	44	07	58	14	70	20	68	23	64	24	68	07
	22	18	17	18	18	19	19	20	20	21	21	22	22	22	23	23	24	24	24	25	25
	0	3	8	0	4	7	2	8	0	5	1	7	2	4	9	6	1	3	8	4	7
	0	16	33	49	68	87	10	12	15	17	19	22	25	27	31	34	37	41	44	48	53
		26	16	87	72	78	80	86	07	37	90	39	15	87	06	04	55	04	92	58	13
							3	7	5	1	4	9	6	7	2	8	2	4	8	8	9

Differences

Table 11. Difference (Baseline relative to Scenario) by disease per 100,000 and deaths by year per 100,000 in South Lakeland

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037
[B-S]asthma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
[B-S]diabetes	0	10	11	21	11	22	22	0	0	11	0	12	0	0	0	13	0	14	0	0	15
[B-S]lung cancer	0	0	0	0	1	1	1	0	1	0	1	1	0	0	2	1	0	1	0	0	2
[B-S]deaths	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

PM2.5

Baseline

Table 12. Baseline prevalence by disease by year per 100,000 of the surviving cohort population and deaths by year per 100,000 in South Lakeland

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037
[B] coronary heart disease	34	35	35	36	36	36	37	37	37	38	38	38	38	39	39	39	40	40	40	41	41
[B] copd	29	26	23	21	19	18	16	15	14	13	12	12	11	11	11	11	10	10	10	10	10
[B] stroke	38	38	37	37	37	36	36	36	36	36	35	35	35	35	35	35	35	35	35	35	36
[B] asthma	12	12	12	13	13	13	13	13	14	14	14	14	15	15	15	15	15	15	16	16	16
[B] diabetes	71	78	84	90	96	10	10	11	12	12	13	13	14	14	15	15	15	16	16	17	17
[B] lung cancer	22	18	17	17	17	17	18	18	19	19	20	20	21	21	21	22	22	23	23	24	24
[B] deaths	0	20	41	61	84	10	12	15	17	20	22	25	28	31	34	37	41	45	49	52	57

Scenario

Table 13. Scenario prevalence by disease by year per 100,000 of the surviving cohort population and deaths by year per 100,000 in South Lakeland

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037
[S] coronary heart disease	34	35	35	36	36	36	37	37	37	38	38	38	38	39	39	39	39	40	40	41	41
[S] copd	29	26	23	21	19	18	16	15	14	13	12	12	11	11	11	11	10	10	10	10	10
[S] stroke	38	38	37	37	37	36	36	36	36	36	35	35	35	35	35	35	35	35	35	36	36
[S] asthma	12	12	12	13	13	13	13	13	14	14	14	14	15	15	15	15	15	15	16	16	16
[S] diabetes	71	78	84	90	96	10	10	11	12	12	13	13	14	14	15	15	15	16	16	17	17
[S] lung cancer	22	18	17	17	17	17	18	18	19	19	20	20	21	21	21	22	22	23	23	24	24
[S] deaths	0	20	41	61	84	10	12	15	17	20	22	25	28	31	34	37	41	45	49	52	57

Differences

Table 14. Difference (Baseline relative to Scenario) by disease per 100,000 and deaths by year per 100,000 in South Lakeland

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037
[B-S]coronary heart disease	0	0	0	0	0	0	11	0	0	0	0	0	13	0	0	13	14	14	0	15	0
[B-S]copd	0	0	0	0	0	0	0	0	0	0	0	2	2	2	1	1	2	1	1	2	2
[B-S]stroke	0	0	0	0	0	0	0	0	0	0	0	0	0	13	0	0	0	0	0	0	0
[B-S]asthma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
[B-S]diabetes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
[B-S]lung cancer	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
[B-S]deaths	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Economic results

Lambeth

NO2

Baseline

Table 15. Baseline Costs by year per 100,000 of the surviving cohort population and deaths by year per 100,000 in Lambeth

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037
[B] Primary Care	56	69	81	94	63	82	04	26	39	55	75	91	06	22	31	49	63	90	70	17	01
[B] Primary Care Costs	95	00	03	93	2	1	1	0	0	5	4	8	0	4	8	1	9	0	4	8	6
[B] Secondary Care	21	40	57	75	32	04	80	56	18	86	57	26	92	57	16	85	51	33	50	62	84
[B] Secondary Care Costs	51	69	06	69	7	6	9	5	8	6	2	3	4	1	0	5	2	7	9	2	8
[B] Medication	12	22	31	40	91	78	66	55	30	15	02	87	65	50	25	12	92	79	34	45	03
[B] Medication Costs	95	44	23	37	62	27	41	15	35	20	45	59	95	67	73	53	29	97	93	15	89
[B] Social Care	04	25	45	66	56	49	45	42	26	14	05	93	81	66	45	33	19	24	56	91	27
[B] Social Care Costs	71	90	58	06	52	39	26	68	93	38	89	34	25	02	26	15	43	99	39	11	46
[B] Combined	7.95	8.57	9.15	9.76	10.34	10.91	11.49	12.08	12.61	13.17	13.74	14.29	14.84	15.39	15.91	16.48	17.02	17.62	18.01	18.71	19.11
[B] Combined Costs	62.58	81.88	91.37	42.42	40.26	54.05	61.97	13.88	54.73	16.79	14.19	86.83	64.65	95.75	95.55	08.22	72.01	91.50	28.67	61.71	79.66

Scenario

Table 16. Scenario Costs by disease by year per 100,000 of the surviving cohort population and deaths by year per 100,000 in Lambeth

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037
[S]	1.	1.	1.	1.	2.0	2.1	2.2	2.3	2.4	2.5	2.6	2.7	2.8	2.9	3.0	3.1	3.2	3.3	3.4	3.5	3.6
Primary Care	56	67	78	90	12	21	27	36	44	46	52	63	65	66	69	75	78	85	82	86	99
Costs	95	05	70	56	6	7	5	5	3	8	9	3	6	9	4	7	2	7	9	7	7
[S]	2.	2.	2.	2.	2.8	3.0	3.1	3.3	3.4	3.6	3.7	3.9	4.0	4.2	4.3	4.5	4.6	4.8	4.9	5.1	5.2
Secondary Care	21	38	53	70	59	16	69	26	82	28	81	41	89	34	83	37	85	39	80	30	94
Costs	85	00	86	00	68	94	39	26	33	21	11	42	41	48	67	03	81	85	69	72	09
[S]	2.	2.	2.	2.	2.4	2.5	2.6	2.6	2.7	2.8	2.9	2.9	3.0	3.1	3.1	3.2	3.3	3.4	3.4	3.5	3.6
Medication	12	21	29	37	54	33	02	81	60	27	04	86	54	22	99	71	41	22	89	62	41
Costs	95	32	31	40	28	11	79	44	42	42	81	10	91	80	39	49	64	33	90	17	03
[S]	2.	2.	2.	2.	2.7	2.9	3.1	3.3	3.4	3.6	3.8	3.9	4.1	4.3	4.4	4.6	4.8	4.9	5.1	5.3	5.5
Social Care	04	23	41	59	75	51	25	00	75	41	11	90	57	22	87	60	28	99	57	26	09
Costs	71	46	42	60	37	61	19	60	30	35	67	32	69	46	95	88	16	05	74	40	06
[S]	7.	8.	9.	9.	10.	10.	11.	11.	12.	12.	13.	13.	14.	14.	15.	15.	16.	16.	17.	17.	18.
Combined	95	50	03	57	10	62	12	64	16	64	14	68	16	64	14	64	13	64	11	60	14
Costs	62	52	45	13	18	34	49	47	30	31	97	10	76	61	06	50	38	65	12	60	35
Costs	58	58	70	99	35	78	29	06	11	90	10	97	18	52	71	59	90	40	33	43	32

Differences

Table 17. Difference (Baseline relative to Scenario) by Costs per 100,000 and deaths by year per 100,000 in Lambeth

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037
[B-S]	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.
Primary Care Costs	00	01	02	04	05	06	07	09	10	12	12	14	15	16	17	18	20	18	23	20	20
[B-S]	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	1.	1.	1.	1.	1.	2.	2.	2.	2.
Cumulative Primary Care Costs	00	01	04	08	13	19	26	36	45	56	68	81	95	11	27	44	63	83	02	25	46
[B-S]	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.
Secondary Care Costs	00	02	03	05	07	08	11	13	13	15	17	18	20	22	23	24	26	29	26	33	29
[B-S]	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	1.	1.	1.	1.	2.	2.	2.	2.	3.	3.
Cumulative Secondary Care Costs	00	02	06	11	19	27	39	52	65	81	99	17	37	60	83	08	35	64	91	24	53
[B-S]	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.
Medication Costs	00	12	91	97	73	51	36	37	99	77	76	14	10	78	63	10	06	76	50	29	28
[B-S]	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.
Cumulative Medication Costs	00	01	03	06	09	14	20	27	34	43	53	63	74	87	00	14	29	45	59	77	94
[B-S]	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.
Social Care Costs	00	02	04	06	08	09	12	14	15	17	19	20	22	24	25	27	29	32	29	36	31
[B-S]	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.
Cumulative Social Care Costs	00	02	06	13	21	30	42	57	72	89	09	29	51	76	01	29	58	90	20	57	88
[B-S]	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.
Combined Costs	00	07	12	19	24	29	37	43	45	52	59	61	67	75	77	83	89	98	90	11	97
Costs	00	29	45	28	21	19	12	66	24	84	17	75	88	04	88	57	33	26	16	01	44

00 30 66 42 90 26 68 82 64 88 10 87 47 23 84 61 11 09 37 30 36

PM2.5

Baseline

Table 18. Baseline Costs by disease by year per 100,000 of the surviving cohort population and deaths by year per 100,000 in Lambeth

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	
[B] Primary Care Costs	2.1	2.2	2.3	2.4	2.5	2.6	2.7	2.8	2.9	3.1	3.2	3.3	3.4	3.5	3.6	3.8	3.9	4.0	4.1	4.3	4.4	
[B] Secondary Care Costs	5.6	5.8	6.0	6.2	6.4	6.6	6.8	7.0	7.2	7.4	7.6	7.9	8.1	8.3	8.5	8.8	9.0	9.3	9.5	9.8	10.0	
[B] Medication Costs	3.9	4.1	4.2	4.3	4.4	4.5	4.6	4.7	4.8	4.9	5.0	5.1	5.2	5.4	5.5	5.6	5.7	5.9	6.0	6.1	6.3	
[B] Social Care Costs	2.3	2.5	2.7	2.9	3.1	3.3	3.5	3.7	3.9	4.1	4.3	4.5	4.6	4.8	5.0	5.2	5.4	5.6	5.7	5.9	6.2	
[B] Combined Costs	14.1	14.8	15.1	16.0	16.7	17.1	17.8	18.1	19.1	19.2	20.1	20.2	21.1	22.1	22.2	23.1	23.2	24.1	24.2	25.1	26.1	27.1

Scenario

Table 19. Scenario Costs by disease by year per 100,000 of the surviving cohort population and deaths by year per 100,000 in Lambeth

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	
[S] Primary Care Costs	2.1	2.2	2.2	2.3	2.4	2.5	2.6	2.7	2.7	2.8	2.9	3.0	3.1	3.2	3.3	3.5	3.6	3.7	3.8	3.9	4.0	
[S] Secondary Care Costs	5.6	5.7	5.8	5.9	6.0	6.2	6.3	6.5	6.6	6.7	6.9	7.1	7.2	7.4	7.6	7.8	7.9	8.2	8.3	8.6	8.8	
[S] Medication Costs	3.9	4.0	4.1	4.1	4.2	4.3	4.3	4.4	4.5	4.6	4.6	4.7	4.8	4.9	5.0	5.1	5.2	5.3	5.4	5.5	5.6	
[S] Social Care Costs	2.3	2.5	2.7	2.9	3.0	3.2	3.4	3.5	3.7	3.9	4.0	4.2	4.3	4.5	4.7	4.8	5.0	5.2	5.3	5.5	5.7	
[S] Combined Costs	14.1	14.4	14.7	15.1	15.6	16.1	16.7	17.1	17.8	18.1	18.8	19.1	19.2	20.1	20.2	21.1	21.2	22.1	22.2	23.1	23.2	24.1

Differences

Table 20. Difference (Baseline relative to Scenario) by Costs per 100,000 and deaths by year per 100,000 in Lambeth

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037
[B-S]	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.2	0.2	0.2	0.2	0.3	0.3	0.3	0.3	0.3	0.4
Primary Care Costs	00	02	05	08	10	12	14	17	18	20	22	44	57	77	90	14	27	38	46	67	12
[B-S]	0.	0.	0.	0.	0.	0.	0.	0.	0.	1.	1.	1.5	1.8	2.1	2.4	2.7	3.0	3.3	3.7	4.1	4.5
Cumulative Primary Care Costs	00	02	08	17	27	40	54	71	90	11	33	81	38	16	06	20	48	87	33	00	13
[B-S]	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.8	0.8	0.9	0.9	1.0	1.1	1.1	1.1	1.1	1.3
Secondary Care Costs	00	10	19	26	34	42	48	56	62	69	75	17	65	30	69	56	09	53	90	60	40
[B-S]	0.	0.	0.	0.	0.	1.	1.	2.	3.	4.	5.2	6.1	7.0	8.0	9.1	10.	11.	12.	13.	15.	15.
Cumulative Secondary Care Costs	00	10	29	56	90	33	82	38	01	71	46	79	44	74	43	00	20	36	55	81	15
[B-S]	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.4	0.4	0.4	0.4	0.5	0.5	0.5	0.5	0.6	0.6	0.6
Medication Costs	00	05	09	13	17	21	23	28	31	34	38	10	42	69	89	45	73	89	10	46	88
[B-S]	0.	0.	0.	0.	0.	0.	0.	1.	1.	2.	2.6	3.0	3.5	4.0	4.5	5.1	5.7	6.3	7.0	7.7	7.7
Cumulative Medication Costs	00	05	14	28	45	66	90	19	50	85	23	49	92	62	52	97	70	60	70	17	06
[B-S]	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.2	0.2	0.3	0.3	0.3	0.3	0.4	0.4	0.4	0.5	0.5
[B-S] Social Care Costs	00	03	06	09	11	14	16	19	21	23	25	82	97	24	41	68	86	00	09	35	03
[B-S]	0.	0.	0.	0.	0.	0.	0.	0.	1.	1.	1.	1.7	2.0	2.4	2.7	3.1	3.4	3.8	4.3	4.7	5.2
Cumulative Social Care Costs	00	03	09	18	29	43	60	79	00	24	49	79	77	02	43	11	98	99	08	44	47
[B-S]	0.	0.	0.	0.	0.	1.	1.	1.	1.	1.	1.7	1.8	2.0	2.0	2.2	2.3	2.4	2.5	2.7	2.9	2.9
Combined Costs	00	21	40	57	73	90	03	21	34	48	61	55	63	02	90	83	96	82	56	10	45
[B-S]	0.	0.	0.	0.	0.	0.	1.	1.	1.	1.	1.7	1.8	2.0	2.0	2.2	2.3	2.4	2.5	2.7	2.9	2.9
Cumulative Combined Costs	00	21	62	20	93	84	87	09	43	92	53	29	15	24	53	92	41	96	67	62	62
[B-S]	0.	0.	0.	1.	1.	2.	3.	5.	6.	7.	9.	11.	13.	15.	17.	19.	21.	24.	26.	29.	32.
Combined Costs	00	61	72	31	64	71	43	69	47	58	59	07	45	90	32	14	98	61	92	41	80

South Lakeland

NO2

Baseline

Table 21. Baseline prevalence by Costs by year per 100,000 of the surviving cohort population and deaths by year per 100,000 in South Lakeland

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037
[B] Primary Care Costs	2.9	3.1	3.3	3.5	3.6	3.8	3.9	4.1	4.2	4.3	4.4	4.6	4.6	4.7	4.8	4.9	5.0	5.1	5.1	5.2	5.3
[B] Secondary Care Costs	69	61	38	10	71	26	75	16	46	81	84	23	93	99	83	95	46	35	92	41	16
[B] Medication Costs	37	69	79	87	37	16	53	48	48	53	23	29	42	90	13	25	42	34	74	78	48
[B] Social Care Costs	4	4	6	5	3	6	7	6	5	4	5	2	0	8	3	1	0	6	5	4	7
[B] Combined Costs	4.2	4.5	4.8	5.0	5.2	5.5	5.7	5.9	6.1	6.2	6.4	6.6	6.7	6.9	7.0	7.1	7.2	7.3	7.4	7.5	7.6
[S] Primary Care Costs	94	53	04	50	80	02	17	19	05	99	47	47	48	00	20	82	55	82	65	36	43
[S] Secondary Care Costs	23	86	33	32	77	63	06	74	98	40	80	88	54	60	84	51	80	84	33	15	56
[S] Medication Costs	7	4	0	9	6	9	3	4	1	5	3	9	6	9	0	8	1	0	6	6	1
[S] Social Care Costs	3.0	3.2	3.3	3.4	3.5	3.7	3.8	3.9	4.0	4.1	4.1	4.2	4.3	4.4	4.4	4.5	4.5	4.6	4.6	4.7	4.7
[S] Medication Costs	75	18	50	78	99	08	21	21	14	17	91	91	42	19	81	55	94	61	98	34	86
[S] Social Care Costs	60	62	63	48	36	71	94	68	10	93	87	90	48	22	36	29	67	18	23	99	99
[S] Combined Costs	0	0	6	0	8	6	4	7	7	9	3	4	5	5	9	3	2	7	4	9	9
[S] Primary Care Costs	4.3	4.6	4.9	5.2	5.4	5.7	5.9	6.1	6.4	6.6	6.7	7.0	7.1	7.2	7.4	7.6	7.6	7.8	7.9	8.0	8.1
[S] Secondary Care Costs	51	58	42	18	74	24	63	91	01	16	81	06	19	91	24	08	89	31	26	04	26
[S] Social Care Costs	03	86	34	01	37	99	24	38	59	30	96	27	33	03	23	24	58	83	40	81	13
[S] Combined Costs	0	6	2	1	0	6	5	5	2	9	0	9	8	9	6	5	2	1	4	8	6
[S] Primary Care Costs	14.	15.	16.	17.	18.	18.	19.	20.	20.	21.	21.	22.	22.	23.	23.	24.	24.	25.	25.	25.	25.
[S] Secondary Care Costs	69	59	43	25	02	76	47	14	76	41	90	56	90	41	80	34	58	01	28	51	87
[S] Social Care Costs	02	30	61	76	58	25	77	93	81	51	58	93	37	07	95	13	64	12	27	77	31
[S] Combined Costs	42	43	02	94	87	16	89	03	66	88	70	63	90	82	78	05	72	02	19	54	84

Scenario

Table 22. Scenario Costs by year per 100,000 of the surviving cohort population and deaths by year per 100,000 in South Lakeland

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037
[S] Primary Care Costs	2.9	3.1	3.3	3.5	3.6	3.8	3.9	4.1	4.2	4.3	4.4	4.5	4.6	4.7	4.8	4.9	5.0	5.0	5.1	5.2	5.2
[S] Secondary Care Costs	69	58	34	03	67	18	67	16	46	42	84	84	93	99	83	55	46	94	92	41	73
[S] Medication Costs	37	00	79	34	44	46	95	48	43	91	19	18	42	90	05	15	42	41	74	78	72
[S] Social Care Costs	4	0	4	9	1	8	4	6	9	2	0	8	0	8	0	3	0	1	5	4	6
[S] Combined Costs	4.2	4.5	4.7	5.0	5.2	5.4	5.7	5.9	6.1	6.2	6.4	6.5	6.7	6.9	7.0	7.1	7.2	7.3	7.4	7.5	7.5
[S] Primary Care Costs	94	48	98	39	74	91	05	19	05	44	47	91	48	00	20	24	55	23	65	36	81
[S] Secondary Care Costs	23	57	60	55	77	25	85	74	56	12	40	58	54	60	08	81	80	94	33	15	77
[S] Medication Costs	7	7	2	7	9	7	3	4	7	4	2	5	6	9	4	0	1	5	6	6	5
[S] Social Care Costs	3.0	3.2	3.3	3.4	3.5	3.7	3.8	3.9	4.0	4.0	4.1	4.2	4.3	4.4	4.4	4.5	4.5	4.6	4.6	4.7	4.7
[S] Medication Costs	75	15	47	72	96	03	16	21	14	89	91	63	42	19	81	25	94	30	98	34	55
[S] Social Care Costs	60	89	68	92	46	03	35	68	07	42	84	03	48	22	31	68	67	96	23	99	43
[S] Combined Costs	0	3	1	4	8	6	0	7	6	2	3	4	5	5	3	9	2	6	4	9	1
[S] Primary Care Costs	4.3	4.6	4.9	5.2	5.4	5.7	5.9	6.1	6.4	6.5	6.7	6.9	7.1	7.2	7.4	7.5	7.6	7.7	7.9	8.0	8.0
[S] Secondary Care Costs	51	52	35	05	68	12	51	91	01	54	81	43	19	91	24	43	89	66	26	04	57
[S] Social Care Costs	03	94	92	93	05	64	07	38	51	35	88	54	33	03	09	91	58	15	40	81	53
[S] Combined Costs	0	1	1	8	7	2	6	5	3	2	3	4	8	9	1	5	2	9	4	8	1
[S] Primary Care Costs	14.	15.	16.	17.	18.	18.	19.	20.	20.	21.	21.	22.	22.	23.	23.	24.	24.	24.	25.	25.	25.
[S] Secondary Care Costs	69	57	41	22	00	72	44	14	76	23	90	38	90	41	80	14	58	81	28	51	66
[S] Social Care Costs	02	54	69	17	67	54	12	93	75	08	53	23	37	07	85	95	64	54	27	77	84
[S] Combined Costs	42	10	96	67	44	03	33	03	95	10	17	51	90	82	37	67	72	81	19	54	61

Differences

Table 23. Difference (Baseline relative to Scenario) by Costs per 100,000 and deaths by year per 100,000 in South Lakeland

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037
[B-S]	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Primary Care Costs	00	00	00	00	00	00	00	00	00	03	00	03	00	00	00	04	00	04	00	00	04
[B-S] Cumulative Primary Care Costs	00	36	40	75	39	76	75	00	00	86	00	91	00	00	00	00	00	09	00	00	27
[B-S] Secondary Care Costs	00	94	02	26	32	98	82	00	46	22	44	04	00	00	84	98	00	35	00	00	62
[B-S] Cumulative Secondary Care Costs	00	00	00	01	01	02	03	03	03	07	07	11	11	11	11	15	15	19	19	19	23
[B-S] Medication Costs	00	36	76	52	91	68	44	44	44	31	31	22	22	22	23	24	24	33	33	33	61
[B-S] Cumulative Medication Costs	00	94	96	22	54	51	33	33	79	01	46	50	50	50	34	32	32	67	67	67	28
[B-S] Social Care Costs	00	00	00	01	00	01	01	00	00	05	00	05	00	00	00	05	00	05	00	00	06
[B-S] Cumulative Social Care Costs	00	52	57	07	59	13	12	00	04	52	04	63	00	00	07	77	00	88	00	00	17
[B-S] Medication Costs	00	87	28	72	97	82	11	00	13	82	01	03	00	00	55	07	00	95	00	00	86
[B-S] Cumulative Medication Costs	00	00	01	02	02	03	05	05	05	10	10	16	16	16	16	22	22	28	28	28	34
[B-S] Social Care Costs	00	52	10	17	77	91	03	03	07	60	64	27	27	27	35	12	12	01	01	01	19
[B-S] Cumulative Social Care Costs	00	87	15	88	85	66	77	77	91	72	74	77	77	77	32	39	39	34	34	34	20
[B-S] Medication Costs	00	00	00	00	00	00	00	00	00	02	00	02	00	00	00	02	00	03	00	00	03
[B-S] Cumulative Medication Costs	00	27	29	55	29	56	55	00	00	85	00	88	00	00	00	96	00	02	00	00	15
[B-S] Social Care Costs	00	27	55	57	00	81	95	00	31	17	30	70	00	00	57	04	00	22	00	00	68
[B-S] Cumulative Social Care Costs	00	00	00	01	01	01	02	02	02	05	05	08	08	08	08	11	11	14	14	14	17
[B-S] Medication Costs	00	27	56	12	41	98	54	54	54	39	39	28	28	28	29	25	25	27	27	27	43
[B-S] Social Care Costs	00	27	82	39	39	20	15	15	46	63	93	63	63	63	19	23	23	45	45	45	13
[B-S] Cumulative Social Care Costs	00	00	00	01	00	01	01	00	00	06	00	06	00	00	00	06	00	06	00	00	06
[B-S] Medication Costs	00	59	64	20	63	23	21	00	00	19	00	27	00	00	01	43	00	56	00	00	86
[B-S] Social Care Costs	00	25	20	73	13	54	69	00	79	57	77	35	00	00	45	29	00	71	00	00	06
[B-S] Cumulative Social Care Costs	00	00	01	02	03	04	05	05	05	11	11	18	18	18	18	24	24	31	31	31	37
[B-S] Medication Costs	00	59	23	44	07	30	52	52	53	72	73	01	01	01	02	45	45	02	02	02	88
[B-S] Social Care Costs	00	25	46	18	31	85	54	54	33	90	67	01	01	01	46	75	75	46	46	46	52
[B-S] Combined Costs	00	01	01	03	01	03	03	00	00	18	00	18	00	00	00	19	00	19	00	00	20
[B-S] Cumulative Combined Costs	00	76	91	59	91	71	65	00	05	43	05	70	00	00	10	17	00	57	00	00	47
[B-S] Medication Costs	00	33	06	28	42	14	57	00	70	77	53	12	00	00	40	39	00	22	00	00	22
[B-S] Social Care Costs	00	01	03	07	09	12	16	16	16	35	35	53	53	53	53	73	73	92	92	92	13
[B-S] Cumulative Combined Costs	00	76	67	26	18	89	54	54	60	04	09	79	79	79	90	07	07	64	64	64	12
[B-S] Medication Costs	00	33	39	67	09	22	79	79	49	26	79	91	91	91	31	70	70	91	91	91	14

PM2.5

Baseline

Table 24. Baseline prevalence by Costs by year per 100,000 of the surviving cohort population and deaths by year per 100,000 in South Lakeland

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037
[B] Primary Care	4.5	4.5	4.6	4.7	4.7	4.8	4.9	5.0	5.1	5.1	5.2	5.3	5.3	5.4	5.5	5.6	5.6	5.7	5.7	5.8	5.8
Costs	16	91	45	27	98	87	56	46	36	99	66	47	94	87	43	13	47	30	72	20	41
[B] Secondary Care	47	85	24	34	59	71	54	00	08	59	98	03	76	64	76	24	49	04	10	28	33
Costs	3	4	4	7	1	7	0	6	6	6	1	8	0	1	6	0	4	5	7	4	6
[B] Medication	13.	13.	13.	13.	13.	13.	14.	14.	14.	14.	14.	14.	14.	14.	14.	14.	14.	14.	14.	14.	14.
Costs	71	83	83	93	91	99	01	07	09	10	12	19	14	20	21	30	25	33	33	43	37
[B] Combined	61	27	75	26	59	20	21	80	12	99	23	02	37	35	51	49	40	85	83	34	16
Costs	61	69	72	16	62	88	04	66	25	12	69	78	77	85	80	99	16	43	91	15	00
[B] Social Care	8.1	8.2	8.3	8.4	8.4	8.4	8.5	8.5	8.5	8.5	8.5	8.6	8.6	8.6	8.6	8.6	8.6	8.6	8.6	8.7	8.6
Costs	43	69	25	11	29	83	19	59	78	89	99	34	08	36	34	80	51	86	87	30	90
[B] Primary Care	37	21	13	60	03	63	48	66	74	64	19	38	57	63	21	51	02	73	69	70	51
Costs	9	1	4	2	7	0	0	9	3	1	4	4	9	5	2	2	0	1	9	6	5
[B] Secondary Care	5.2	5.5	5.8	6.0	6.3	6.5	6.7	6.9	7.1	7.2	7.4	7.6	7.7	7.8	8.0	8.1	8.2	8.3	8.4	8.5	8.5
Costs	61	55	19	74	02	32	36	40	45	90	46	06	16	85	04	27	00	44	24	08	54
[B] Combined	22	50	84	20	43	26	86	73	27	85	99	20	69	93	83	35	39	33	80	61	59
Costs	3	7	5	8	8	9	3	7	2	9	2	5	1	1	8	3	3	0	3	7	7
[B] Medication	31.	32.	32.	33.	33.	33.	34.	34.	34.	35.	35.	35.	35.	36.	36.	36.	36.	37.	37.	37.	37.
Costs	63	24	62	14	44	89	22	62	95	19	43	77	86	21	39	72	75	09	22	49	45
[B] Social Care	72	93	77	57	60	57	49	44	13	00	55	79	38	37	79	61	29	96	30	30	80
Costs	34	44	92	75	26	06	83	77	24	06	35	05	04	91	91	05	26	48	03	23	46

Scenario

Table 25. Scenario prevalence by Costs by year per 100,000 of the surviving cohort population and deaths by year per 100,000 in South Lakeland

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037
[S] Primary Care	4.5	4.5	4.6	4.7	4.7	4.8	4.9	5.0	5.1	5.1	5.2	5.3	5.3	5.4	5.5	5.6	5.6	5.7	5.7	5.8	5.8
Costs	16	91	45	27	98	87	55	46	36	99	66	46	93	86	43	12	46	28	71	18	40
[S] Secondary Care	47	85	24	34	59	71	82	00	08	59	98	31	31	59	44	17	07	96	80	87	74
Costs	3	4	4	7	1	7	2	6	6	6	1	6	6	3	2	9	9	1	1	7	4
[S] Medication	13.	13.	13.	13.	13.	13.	14.	14.	14.	14.	14.	14.	14.	14.	14.	14.	14.	14.	14.	14.	14.
Costs	71	83	83	93	91	99	07	09	10	12	18	12	19	21	28	23	32	33	41	37	
[S] Combined	61	27	75	26	59	20	74	80	12	99	23	88	69	48	47	93	70	22	79	60	07
Costs	61	69	72	16	62	88	31	66	25	12	69	87	61	99	05	95	40	75	43	93	32
[S] Social Care	8.1	8.2	8.3	8.4	8.4	8.4	8.5	8.5	8.5	8.5	8.5	8.6	8.5	8.6	8.6	8.6	8.6	8.6	8.6	8.7	8.6
Costs	43	69	25	11	29	83	11	59	78	89	99	34	99	31	34	71	41	77	87	21	90
[S] Primary Care	37	21	13	60	03	63	25	66	74	64	19	13	49	04	10	92	82	77	60	30	32
Costs	9	1	4	2	7	0	6	9	3	1	4	9	0	2	9	8	2	1	3	3	7
[S] Secondary Care	5.2	5.5	5.8	6.0	6.3	6.5	6.7	6.9	7.1	7.2	7.4	7.6	7.7	7.8	8.0	8.1	8.1	8.3	8.4	8.5	8.5
Costs	61	55	19	74	02	32	35	40	45	90	46	05	15	84	04	26	99	43	24	07	54
[S] Combined	22	50	84	20	43	26	76	73	27	85	99	98	35	97	76	14	05	07	73	25	47
Costs	3	7	5	8	8	9	0	7	2	9	2	6	9	9	8	7	4	7	8	5	2
[S] Medication	31.	32.	32.	33.	33.	33.	34.	34.	34.	35.	35.	35.	35.	36.	36.	36.	36.	37.	37.	37.	37.
Costs	63	24	62	14	44	89	20	62	95	19	43	77	83	19	39	69	72	07	22	46	45
[S] Social Care	72	93	77	57	60	57	02	44	13	00	55	53	51	75	70	96	39	20	20	35	62
Costs	34	44	92	75	26	06	68	77	24	06	35	30	25	10	22	54	95	83	88	28	72

Differences

Table 26. Difference (Baseline relative to Scenario) by Costs per 100,000 and deaths by year per 100,000 in South Lakeland

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037
[B-S]	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.
Primary Care Costs	00	00	00	00	00	00	00	07	00	00	00	00	00	00	00	00	00	00	00	00	00
[B-S] Cumulative Primary Care Costs	00	00	00	00	00	00	19	00	00	00	00	22	44	47	24	61	16	85	05	07	92
[B-S] Secondary Care Costs	00	00	00	00	00	00	01	00	00	00	00	00	01	00	00	01	01	01	00	01	00
[B-S] Cumulative Secondary Care Costs	00	00	00	00	00	00	46	00	00	00	00	13	68	86	04	56	69	62	04	73	08
[B-S] Medication Costs	00	00	00	00	00	00	00	00	00	00	00	00	00	00	00	00	00	00	00	00	00
[B-S] Cumulative Medication Costs	00	00	00	00	00	00	82	00	00	00	00	02	90	55	01	85	91	89	00	94	01
[B-S] Social Care Costs	00	00	00	00	00	00	24	00	00	00	00	44	88	93	03	84	98	62	97	04	87
[B-S] Cumulative Social Care Costs	00	00	00	00	00	00	82	82	82	82	82	84	75	31	32	18	10	99	00	94	96
[B-S] Combined Costs	00	00	00	00	00	00	24	24	24	24	24	68	57	49	52	36	34	96	92	97	84
[B-S] Cumulative Combined Costs	00	00	00	00	00	00	11	11	11	11	11	13	26	36	36	48	62	74	75	89	90
[B-S] Combined Costs	00	00	00	00	00	00	02	00	00	00	00	00	02	01	00	02	02	02	00	02	00
[B-S] Cumulative Combined Costs	00	00	00	00	00	00	47	00	00	00	00	25	86	62	09	64	89	75	09	94	17
[B-S] Combined Costs	00	00	00	00	00	00	17	00	00	00	00	77	81	79	71	53	30	68	14	94	74
[B-S] Cumulative Combined Costs	00	00	00	00	00	00	02	02	02	02	02	05	07	07	09	12	15	15	18	18	18
[B-S] Combined Costs	00	00	00	00	00	00	47	47	47	47	47	72	59	22	32	96	86	61	70	65	83
[B-S] Cumulative Combined Costs	00	00	00	00	00	00	17	17	17	17	17	94	75	54	25	78	08	77	91	85	59

Appendix 3: How are costs calculated?

Following the simulation run, the tool simply scales the aggregated individual disease costs according to the relative disease prevalence in years after the start year.

In any year, the total healthcare cost for the disease D is denoted $C_D(\text{year})$. If the prevalence of the disease is denoted $P_D(\text{year})$ we assume a simple relationship between the two of the form
for some constant κ , where κ is defined as the cost per case

$$C_D(\text{year}) = \kappa P_D(\text{year})$$

Appendix 4: Explaining asthma scenario outputs

Asthma is treated as a chronic, fatal disease within the tool. However, there is some instability in the tool outputs for asthma that can be explained by a number of factors: impact from other diseases, type of cohort run (high exposure vs. all exposure groups), level of exposure in the population (for example, Lambeth is high, South Lakeland is low).

The following relative risks (RR) for asthma are included within the tool:

Respiratory outcomes					
				PM _{2.5}	NO ₂
Asthma (children <18 years)	Chronic	Yes	Child	Khreis et al. 2016 (9) In children >6 years: OR 1.04 (1.02; 1.07) per 1µg/m ³ →Converted OR 1.48 (1.22 ; 1.97) per 10µg/m³	Khreis et al. 2016 (9) In children =<6 years : OR 1.08 (1.04; 1.12) per 4µg/m ³ →Converted to OR 1.212 (1.103; 1.328) per 10µg/m ³ →REDUCED by 60% → 1.08 (1.01; 1.12) per 10µg/m³ In children >6 years: OR 1.03 (1.00; 1.06) per 4µg/m ³ →Converted to OR 1.08 (1.00; 1.16) per 10µg/m ³ →REDUCED by 60% → 1.03 (1.00; 1.06) per 10µg/m³
Asthma (adults)	Chronic	Yes	Adult	NOT MODELLED	Jaquemin et al. 2015 (10) In adults: OR 1.10 (0.99;1.21) per 10µg/m ³ →REDUCED by 60% → 1.04 (0.996; 1.08) per 10µg/m³

The following examples provide some explanation for the results observed for asthma. The scenario '100% attributable cases' is run for each example.

PM_{2.5}

For PM_{2.5}, a RR for children above age 6 years was available. Therefore, individuals who live in a high exposure area have an increased risk of contracting asthma if they are aged between 7 and 18 years compared to those living in a low exposure area. For all other individuals the risk is equal.

Example 1: 18+ cohort, all exposure groups, England

When we run this cohort we see that moving 100% of people from a high exposure area to low exposure area results in instability in the prevalence cases avoided and in some years fewer cases of asthma in the high exposure area compared to low exposure group ('negative cases avoided – see Figure 21). This is because adults do not have a differing risk of asthma in the high vs low exposure areas. However, they do have an increased risk of other diseases, therefore, people may have died of diseases such as CHD, COPD, lung cancer in the high exposure group, while those in the low exposure group have survived and continue to live with asthma. Therefore, these results should not be interpreted in isolation.

We can see this more clearly when we run asthma alone in the tool, thus removing any possibility of additional impacts from other diseases. Here we see that, since there are no RR for adults, it makes no difference to the prevalence of asthma when moving adults from areas of high to low exposure (Figure 22). This also highlights the importance of considering the impact from other PM_{2.5} related diseases within tools.

A tool to test the long term health and cost impacts of air pollution at a local authority level



Figure 21 Asthma prevalence cases avoided as a result of moving 100% from an area of high exposure to low exposure (all diseases considered in the tool)

AIR England											
File View/Graphs Help											
Setup Output: Costs Output: Disease Prevalence Graphics											
Baseline [B]: prevalence by disease by year per 100,000 of the surviving cohort population and deaths by year per 100,000											
Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027
[B] asthma	12900	13157	13318	13480	13657	13833	14018	14314	14408	14607	14823
[B] deaths	0	1204	2449	3691	5053	6406	7828	9266	10828	12360	14025
Scenario [S]: prevalence by disease by year per 100,000 of the surviving cohort population and deaths by year per 100,000											
Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027
[S] asthma	12900	13157	13318	13480	13657	13833	14018	14314	14408	14607	14823
[S] deaths	0	1204	2449	3691	5053	6406	7828	9266	10828	12360	14025
Differences (Baseline relative to Scenario) by disease by year per 100,000 and deaths by year per 100,000											
Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027
[B-S]asthma	0	0	0	0	0	0	0	0	0	0	0
[B-S]deaths	0	0	0	0	0	0	0	0	0	0	0

Figure 22 Asthma prevalence cases avoided as a result of moving 100% from an area of high exposure to low exposure (only asthma in the tool)

Note: The tool is a deterministic model which calculates the probability of representative individuals in a population living with a particular disease. The tool calculates the total prevalence of each disease for an individual from the probability of each disease state. Disease states are defined as a state in which an individual may be living with between one and four different diseases. The total disease prevalence is calculated from taking a weighted average over the whole population.

Example 2: Child cohort (1-18 years), high pollution area, England

A simulation where children in a high pollution area are moved to an area of low pollution has a large and important impact on the prevalence of asthma. This is because, from age 7 years, children have an increased probability of contracting asthma if they live in a high exposure area, compared to a less exposed area (Figure 23)




Figure 23 Asthma prevalence cases avoided as a result of moving 100% of the children from an area of high exposure to low exposure

NO₂

For NO₂ relative risks were available for both adults and children. Again, the scenario '100% move to an area of low exposure' was run.

Example 1. 18+ cohort, all exposure groups, England

There are peaks and troughs of asthma cases avoided when comparing all exposure groups to a cohort where 100% of people have moved to an area of low exposure. A similar pattern is observed with individuals in the high exposure group. Again, impact from other diseases are important to consider here, making the trends unstable, since individuals may die from other air pollution related causes in the high exposure area, so there are fewer people to contract asthma in the high exposure group (Figure 24).

A tool to test the long term health and cost impacts of air pollution at a local authority level




Figure 24 Asthma prevalence cases avoided as a result of moving 100% from an area of high exposure to low exposure (only asthma in the tool)

Similarly with adults exposed to high exposure, there are dips in cases avoided (Figure 25).




Figure 25 Asthma prevalence cases avoided as a result of moving 100% from an area of high exposure to low exposure

Example 2: Child cohort (1-18 years), high pollution area, England

In children in the high exposure group there are peaks and troughs in the cases avoided when ‘100% of individuals move from an area of high exposure to low exposure’. Since we include two RRs for children <6 yrs and >=6 years, then this as children age and move onto a different RR beyond age 6, we see more abrupt/stepped changes which may be due to the RRs and the exposure levels for these two different age groups (Figure 26).

A tool to test the long term health and cost impacts of air pollution at a local authority level




Figure 26 Asthma prevalence cases avoided as a result of moving 100% from an area of high exposure to low exposure

A similar pattern is observed in children of all exposure groups (Figure 27).

A tool to test the long term health and cost impacts of air pollution at a local authority level




Figure 27 Asthma prevalence cases avoided as a result of moving 100% from an area of high exposure to low exposure

References

1. Mills IC, Atkinson RW, Kang S, Walton H, Anderson HR. Quantitative systematic review of the associations between short-term exposure to nitrogen dioxide and mortality and hospital admissions. *BMJ Open*. 2015;5(5).
2. Janke K, Propper C, Henderson J. Do current levels of air pollution kill? The impact of air pollution on population mortality in England. *Health Economics*. 2009;18(9):1031-55.
3. Beatty TK, Shimshack JP. School buses, diesel emissions, and respiratory health. *J Health Econ*. 2011;30(5):987-99.
4. Kaufman JD, Adar SD, Barr RG, Budoff M, Burke GL, Curl CL, et al. Association between air pollution and coronary artery calcification within six metropolitan areas in the USA (the Multi-Ethnic Study of Atherosclerosis and Air Pollution): a longitudinal cohort study. *The Lancet*. 388(10045):696-704.
5. Hoek G, Krishnan RM, Beelen R, Peters A, Ostro B, Brunekreef B, et al. Long-term air pollution exposure and cardio- respiratory mortality: a review. *Environmental Health*. 2013;12(1):1-16.
6. Currie J. Pollution and Infant Health. *Child Dev Perspect*. 2013;7(4):237-42.
7. Statistics OfN. Subnational population projections for England: 2014-based projections 2017. Available from:
<https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationprojections/bulletins/subnationalpopulationprojectionsforengland/2014basedprojections>.
8. National Institute of Clinical Excellence. Discounting of health benefits in special circumstances. 2011.
9. Khreis H, Kelly C, Tate J, Parslow R, Lucas K, Nieuwenhuijsen M. Exposure to traffic-related air pollution and risk of development of childhood asthma: A systematic review and meta-analysis. *Environment international*. 2016.
10. Jacquemin B, Siroux V, Sanchez M, Carsin AE, Schikowski T, Adam M, et al. Ambient air pollution and adult asthma incidence in six European cohorts (ESCAPE). *Environ Health Perspect*. 2015;123(6):613-21.